Checkpoint kinase 1 as a promising target in colorectal cancer management  

作　　者：Wenxue Ma Natalia Baran 

机构地区：[1]Department of Medicine,Sanford Stem Cell Institute,Moores Cancer Center,University of California San Diego,La Jolla,CA 92093,United States [2]Department of Leukemia,The University of Texas MD Anderson Cancer Center,Houston,TX 77030,United States [3]Department of Experimental Hematology,Institute of Hematology and Transfusion Medicine,Warsaw 00-791,Mazowieckie,Poland

出　　处：《World Journal of Clinical Oncology》2025年第4期6-8,共3页世界临床肿瘤学杂志(英文)

摘　　要：This editorial provides insights into the pivotal role of checkpoint kinase 1(CHEK1)as both a biomarker and therapeutic target in colorectal cancer(CRC),based on findings from a recent study by Pang et al.Using single-cell RNA sequencing and immunohistochemistry,the study demonstrates significant CHEK1 overexpression in CRC tissues and identifies nitidine chloride as a potent CHEK1 inhibitor that disrupts DNA damage repair pathways.These findings underscore the therapeutic potential of CHEK1 inhibition and highlight the need for further research to address gaps in CRC treatment.

关 键 词：Colorectal cancer Checkpoint kinase 1 BIOMARKER Therapeutic target Single-cell RNA sequencing Nitidine chloride 

分 类 号：R73[医药卫生—肿瘤]